SEARCH

Current Edition

Congress

As Congress weighs drug price restraints, ICER calls out ‘unsupported’ increases

Congress is considering legislation that could force drugmakers to pay steep rebates to Medicare for patent-protected drugs that have price increases exceeding inflation, as well …

Continue Reading →
Drugs

PhRMA criticizes ICER in latest skirmish over valuing drugs

Industry lobbying group PhRMA on Thursday warned the use of cost-effectiveness estimates like those developed by the Institute for Clinical and Economic Review could force …

Continue Reading →